ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency
March 19, 2024 08:07 ET
|
ClearPoint Neuro, Inc.
ClearPoint Neuro's partner's completed BLA Submission for Upstaza™ would be first disease-modifying treatment for AADC Deficiency in the US.
ClearPoint Neuro Reports Fourth Quarter and Full-Year 2023 Results
March 12, 2024 16:05 ET
|
ClearPoint Neuro, Inc.
ClearPoint Neuro reports 32% growth in fourth quarter as compared to fourth quarter of 2022. Biologics revenue increased 49% YOY.
Journal of Neurosurgery Publication Demonstrates Distinct Advantages of ClearPoint Prism® Neuro Laser Therapy System
March 11, 2024 08:00 ET
|
ClearPoint Neuro, Inc.
ClearPoint Neuro announces peer-reviewed publication showing correlation of software lesion size to histopathology, only FDA-cleared laser with correlation
ClearPoint Neuro Announces Installation and First Procedure Using the ClearPoint Prism® Neuro Laser Therapy System and Navigation System at Kaleida Health in Buffalo
January 24, 2024 16:05 ET
|
ClearPoint Neuro, Inc.
First successful procedure with ClearPoint Prism Neuro Laser Therapy System and Neuro Navigation System by Kaleida Health in Buffalo.
ClearPoint Neuro Reports Second Quarter 2022 Results
August 09, 2022 16:15 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...
ClearPoint Neuro to Announce Second Quarter 2022 Results August 9, 2022
July 26, 2022 16:05 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...
ClearPoint Neuro Congratulates Partner PTC Therapeutics on Being Granted Marketing Authorization by the European Commission for Upstaza™ - First Disease-Modifying Treatment for AADC Deficiency
July 21, 2022 16:20 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...
ClearPoint Neuro Congratulates Neurona Therapeutics on Dosing of Initial Subject in First Clinical Trial of Regenerative Human Cell Therapy in Adults with Drug-Resistant Focal Epilepsy
June 29, 2022 16:05 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...
ClearPoint Neuro Announces Receipt of MDSAP Certification
June 02, 2022 16:05 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...
ClearPoint Neuro Congratulates Partner PTC Therapeutics on Receiving Positive CHMP Opinion for Gene Therapy to Treat AADC Deficiency
May 20, 2022 09:29 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...